This research study is testing whether a new investigational drug that targets eosinophils (a type of white blood cell) could help patients with COPD (chronic obstructive pulmonary disease) control symptoms and reduce exacerbations (flare-ups) that lead to hospitalizations. The new investigational drug will be compared to oral and inhaled corticosteroids, the current standard of care for COPD.
The purpose of this study is to investigate whether the study medication can help people with mild to moderate Alzheimer's Disease improve their mental abilities such as understanding, reasoning, and judgment. The study medication will be given together with an FDA-approved Alzheimer's medication: Aricept® (donepezil), Exelon® (rivastigmine) or Razadyne® (galantamine).
This study is for patients with Stage IV non-small cell lung cancer who have already been treated with chemotherapy. The purpose of this study is to compare the new investigational medicine (LY2835219) versus the standard-of-care treatment with respect to life expectancy outcomes.